



Dear Prolastin Patient & Family,

Talecris Biotherapeutics is announcing a name change for Talecris Direct[®]. Effective October 1, 2007, Talecris Direct will be re-named **Prolastin Direct**. The program will continue to offer you the same comprehensive services tailored to the unique needs of people with alpha-1 antitrypsin deficiency. The new name focuses on who the program was created for, who it is dedicated to serve, and more clearly defines that this very specialized service is offered exclusively for Alphas taking Prolastin.

Prolastin Direct will continue to provide uncomplicated access to program benefits that are specialized for the alpha-1 community, including:

- Insurance verification and coordination
- Alpha-1 Health management
- Home infusion with alpha-1-certified nurses
- Pharmacy services
- Reliable delivery of your Prolastin when and where you need it.

As with Talecris Direct, Centric Health Resources will continue to run the customer call center for Prolastin Direct. Call center representatives are available from 7AM to 6PM, Central Time, Monday through Friday when you call 1-800-305-7881. A member of Centric's pharmacy team is also on call 24 hours a day, 7 days a week.

Importantly, through the Prolastin Direct program, you will continue to receive support from your AlphaNet Coordinator.

If you have any questions related to this name change, or to the benefits of the Prolastin Direct program, please contact Centric at 1-800-305-7881. Thank you for your continued support.

Sincerely,

Charles Gayer
Director, Pulmonary
US Product Management

Your healthcare provider is the single best source of information regarding your health. Please consult your healthcare provider if you have questions about your health or your medications.

About Prolastin[®]

Prolastin[®] is indicated for chronic augmentation therapy of individuals having congenital deficiency of alpha-1

proteinase inhibitor with clinically demonstrable panacinar emphysema. Individuals with selective IgA deficiencies who have known antibody against IgA should not receive Prolastin[®], since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.

Important Safety Information

In clinical studies with Prolastin[®], reactions (none severe) were observed in 1.16% of infusions, the most common events being fever, lightheadedness and dizziness. As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. For additional information on Prolastin[®], please see full prescribing information at www.prolastin.com.

For additional information about Prolastin, please see accompanying full prescribing information.